Cancer Biology

Rearrangement of 3D genome organization in breast cancer epithelial to mesenchymal transition and metastasis organotropism

1. Priyojit Das
2. Rebeca San Martin
3. Tian Hong
4. Rachel Patton McCord

• Curated by eLife

  eLife Assessment

  This valuable study explores the role of spatial genome organization in oncogenic transformation, addressing an ambitious and significant topic. The authors have assembled comprehensive datasets from various subtypes of localized and lung-metastatic breast cancer cells, as well as from healthy and cancerous lung cells. They identified switching patterns in the 3D genome organization of lung-metastatic breast cancer cells, revealing a reconfiguration of genome architecture that resembles that of lung cells. This provides solid evidence with significant biomedical implications for epigenetic regulation in both normal physiology and disease.

Reviewed by eLife

Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies

1. Sander Frank
2. Thomas Persse
3. Ilsa Coleman
4. Armand Bankhead
5. Dapei Li
6. Navonil De-Sarkar
7. Divin Wilson
8. Dmytro Rudoy
9. Manasvita Vashisth
10. Patty Galipeau
11. Michael Yang
12. Brian Hanratty
13. Ruth Dumpit
14. Colm Morrissey
15. Eva Corey
16. R Bruce Montgomery
17. Michael C Haffner
18. Colin C Pritchard
19. Valeri Vasioukhin
20. Gavin Ha
21. Peter S Nelson

• Curated by eLife

  eLife Assessment

  The paper is a fundamental study examining the role of CDK12 loss in prostate cancer. While previous studies have suggested that CDK12 loss confers HRD phenotypes, clinical trials using PARPi in CDK12 altered patients have not demonstrated significant benefit. This work investigates these mechanisms in depth and provides compelling evidence. A comprehensive genomic analysis serves an excellent resource to the field, showing that biallelic CDK12 alterations do not have genomic features of HRd. Moreover, the study explored both acute and chronic deletion of CDK12, with data suggestive of CDK12-altered cells being uniquely sensitive to CDK13 inhibition. While some minor weaknesses have been previously noted by the reviewers, the authors have adequately addressed these concerns with appropriate rigor.

Reviewed by eLife

BEHAV3D Tumor Profiler to map heterogeneous cancer cell behavior in the tumor microenvironment

1. Emilio Rios-Jimenez
2. Anoek Zomer
3. Raphael Collot
4. Mario Barrera Román
5. Sandra F Archidona
6. Hendrikus Ariese
7. Ravian van Ineveld
8. Michiel Kleinnijenhuis
9. Nils Bessler
10. Hannah Johnson
11. Caleb A Dawson
12. Anne Rios
13. Maria Alieva

• Curated by eLife

  eLife Assessment

  This is a useful tool for code-less analysis of patterns in cell migratory behaviours in vivo using intravital microscopy data and allows correlation with spatial features of the tumour microenvironment. There is a clear need for these tools to make quantitative analysis, comparison and interpretation of complex cell tracking data more accessible and solid evidence is provided of its applicability to tracks generated by both proprietary and open tracking software.

Reviewed by eLife

Proteomic profiling of advanced hepatocellular carcinoma identifies predictive signatures of response to treatments

1. Adèle Delamarre
2. Marie Decraecker
3. Jean-Frédéric Blanc
4. Sylvaine Di Tommaso
5. Cyril Dourthe
6. Jean-William Dupuy
7. Mélanie Moreau
8. Nathalie Allain
9. Isabelle Mahouche
10. Julie Giraud
11. Giovanni Bénard
12. Claude Lalou
13. Benoît Pinson
14. Paulette Bioulac-Sage
15. Caroline Toulouse
16. Audrey Morisset
17. Jérôme Boursier
18. Brigitte Le Bail
19. Anne-Aurélie Raymond
20. Frédéric Saltel

Reviewed by PREreview

KDM5 demethylases suppress R-loop-mediated ‘viral mimicry’ and DNA damage in breast cancer cells

1. Lena Lau
2. Kurt Henderson
3. Ahu Turkoz
4. Sara Linker
5. Dorte Schlessinger
6. Brad Townsley
7. Brian Egan
8. Shoba Ragunathan
9. Robert Rollins
10. Xianju Bi
11. Zhijian J Chen
12. Oleg Brodsky
13. Clifford Restaino
14. Murali Gururajan
15. Kristen Jensen-Pergakes
16. Anders Mälarstig
17. Chames Kermi
18. Paul Moore
19. Marie Classon

• Curated by eLife

  eLife Assessment

  This study presents a valuable finding that KDM5 inhibitors may enable a wide therapeutic window as compared to STING agonists or Type I Interferons. The evidence supporting the claims of the authors is convincing. The work will be of broad interest to scientists working in the field of breast cancer research.

Reviewed by eLife

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

1. Kamila J Bienkowska
2. Stephany Gallardo Y
3. Nur S Zainal
4. Matthew Ellis
5. Maria-Antoinette Lopez
6. Judith Austine
7. Sai Pittla
8. Serena J Chee
9. Aiman Alzetani
10. Emily C Shaw
11. Christian H Ottensmeier
12. Gareth J Thomas
13. Christopher J Hanley

Reviewed by Review Commons

FAK modulates glioblastoma stem cell energetics via regulation of glycolysis and glutamine oxidation

1. Roza H. A. Masalmeh
2. John C. Dawson
3. Virginia Alvarez Garcia
4. Morwenna T. Muir
5. Roderick N. Carter
6. Giles Hardingham
7. Cameron Davies
8. Rosina Graham
9. Alex von Kriegsheim
10. Jair Marques Junior
11. Chinmayi Pednekar
12. Steven M. Pollard
13. Neil O. Carragher
14. Valerie G. Brunton
15. Margaret C. Frame

Reviewed by Review Commons

Control of mitochondrial dynamics by dPGC1 limits Yorkie-induced oncogenic growth in Drosophila

1. Wei Qi Guinevere Sew
2. Maria Molano-Fernández
3. Zhiquan Li
4. Artim Lange
5. Nahia Pérez de Ciriza
6. Lene Juel Rasmussen
7. Héctor Herranz

Reviewed by Review Commons

Acquired resistance to sotorasib in KRASG12C mutant NSCLC is vulnerable to PI3K-mTOR pathway inhibition mediated by 4E-BP1 regulator of cap-dependent translation

1. Ismail M Meraz
2. Shuhong Wu
3. Yi Xu
4. Lihui Gao
5. Meng Feng
6. Chenghui Ren
7. Renduo Song
8. Ran Zhang
9. Qi Wang
10. Yuanxin Xi
11. Sung Yun Jung
12. Jing Wang
13. Bingliang Fang
14. Mourad Majidi
15. Jack A Roth

• Curated by eLife

  eLife Assessment

  The authors investigate mechanisms of acquired resistance (AR) to KRAS-G12C inhibitors (sotorasib) in non-small cell lung cancer, proposing that resistance arises from signaling rewiring rather than additional mutations. While the study addresses a valuable clinical question, it is limited by several weaknesses in experimental rigor, data interpretation, and presentation, meaning the strength of evidence is incomplete

Reviewed by eLife

Potent synthetic lethality between PLK1 and EYA-family inhibitors in tumours of the central and peripheral nervous system

1. Christopher B. Nelson
2. Jadon K. Wells
3. Ekaagra Kesarwani
4. Alexander P. Sobinoff
5. Jixuan Gao
6. Karen L. MacKenzie
7. Rebecca C. Poulos
8. Urwah Nawaz
9. Xiang Wang
10. Heide L. Ford
11. Hilda A. Pickett

Reviewed by Review Commons